Home > Newsletters > Drug Industry Daily > FDA Addresses Gender Differences in Revision of ICH QT Guidance on QT Interval Prolongation
Drug Industry Daily
Oct. 15, 2012 | Vol. 11 No. 202
FDA Addresses Gender Differences in Revision of ICH QT Guidance on QT Interval Prolongation
The FDA has revised and clarified a final ICH question-and-answer guidance on the evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.